Eurofins Scientific announced the acquisition of assets to establish a fully-equipped, laboratory campus in Genome Valley, Hyderabad. The acquisition includes a facility capable of supporting large global and Indian pharmaceutical clients as well as small biotech companies in the areas of synthetic organic chemistry, analytical R&D, bioanalytical services (for both large and small molecules), in-vivo pharmacology, safety toxicology and formulation R&D. The laboratories occupy over 90,000 ft2.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
56.84 EUR | -7.73% | -3.53% | -3.63% |
Apr. 24 | CAC40: interest rates soar, pulling back below 8100 pts | CF |
Apr. 24 | EUROFINS SCIENTIFIC : Q1 sees a lacklustre start to the year; 2024 outlook confirmed |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.63% | 12.71B | |
-14.17% | 86.34B | |
+17.86% | 84.49B | |
+10.92% | 29.68B | |
-8.51% | 17.5B | |
-2.67% | 16.67B | |
-0.24% | 15.18B | |
+2.63% | 12.53B | |
-30.53% | 11.89B | |
+26.71% | 11.74B |
- Stock Market
- Equities
- ERF Stock
- News Eurofins Scientific SE
- Eurofins Scientific Expands Presence in Indian Pharmaceutical Market with New Hyderabad Campus